参芪扶正注射液在老年晚期非小细胞肺癌化疗患者中的增强作用

Efficacy of Shenqi Fuzheng injection in advanced non-small cell lung chemotherapy in elderly patients

目的:探讨参芪扶正注射液在老年Ⅲ期、Ⅳ期非小细胞肺癌患者化疗中的作用。方法:将经病理组织学或细胞学检查确诊的Ⅲ期、Ⅳ期老年非小细胞肺癌患者随机分为试验组和对照组。试验组72例采取参芪扶正注射液联合长春瑞滨、卡铂化疗,对照组71例,只采用长春瑞滨、卡铂化疗。每3周为1个周期,化疗4个周期。每2个周期评价疗效,监测治疗前后患者肝肾功能、胃肠道反应、血常规和T细胞亚群的变化。结果:试验组和对照组的有效率分别是48.6%和45.1%(P>0.05),疾病进展(PD)率分别是5.6%和14.1%(P<0.05)。试验组胃肠道反应明显减轻、骨髓抑制较对照组减轻,差异有统计学意义(P<0.05);试验组治疗前后CD8+分别为(35.6±2.3)%和(34.8±3.1)%,CD4+/CD8+分别为(1.23±0.30)%和(1.32±0.18)%,对照组治疗前后CD8+分别为(37.1±2.2)%和(23.8±2.9)%,CD4+/CD8+分别为(1.17±0.36)%和(0.87±0.16)%,两组差异有统计学意义(P<0.05,P<0.01);试验组治疗后KPS评分明显高于对照组(P<0.01)。结论:参芪扶正注射液联合长春瑞滨、卡铂方案治疗老年Ⅲ期、Ⅳ期非小细胞肺癌患者,可使患者KPS评分提高,保护造血功能,提高免疫力,减少胃肠道反应的发生,改善生活质量,明显起到辅助、增效作用。

Objective：To explore the enhancing effect of compound Shenqi Fuzheng injection in chemotherapy for patients with stage Ⅲ and IV non-small cell lung cancer（NSCLC）.Methods：The 143 patients with stage Ⅲ,Ⅳ non-small cell lung cance confirmed by pathology or cytology were randomly divided into the experimental and the control groups,the experimental group including 72 cases was treated by Shenqi Fuzheng injection plus vinorelbine and carboplatin chemotherapy,71 patients in the control group,were only treated by vinorelbine and carboplatin chemotherapy.3 weeks for a cycle,we implemented 4 cycles of chemotherapy.Therapeutic efficacy was evaluated every 2 cycles and to monitor liver and renal function,gastrointestinal reactions,blood,and T cell subsets before and after treatment.Results：The efficiency rate of the experimental and the control groups were 48.6% and 45.1%（P 0.05）,disease progression（PD）rates were 5.6% and 14.1%（P0.05）.The gastrointestinal reactions and bone marrow suppression reduced significantly in the experimental group than the control groups（P0.05）.In the experimental group,CD8＋cells were（35.6±2.3）% and（34.8±3.1）%,CD4＋/CD8＋ were respectively（1.23±0.30）and（1.32±0.18）before and after the treatment,in the control group before and after the treatment,CD8 ＋cells were respectively（37.1±2.2）% and（23.8±2.9）%,CD4＋/CD8＋ were respectively（1.17±0.36）and（0.87±0.16）,the difference was statistically significant（P0.05,P0.01）.KPS score or the experimental group after the treatment was significantly higher（P0.01）.Conclusion：Shenqi Fuzheng injection combined with vinorelbine and carboplatin in the treatment of senile stage Ⅲ,Ⅳ stage non-small cell lung cancer patients can improve KPS scores,protect hematopoietic function,improve immunity,reduce the incidence of gastrointestinal reactions,improve quality of life and obviously play a supporting,synergistic effect.